Royal Bank Of Canada Cuts Moderna (NASDAQ:MRNA) Price Target to $25.00

Moderna (NASDAQ:MRNA) had its price objective lowered by Royal Bank Of Canada from $28.00 to $25.00 in a report published on Friday morning, MarketBeat reports. The brokerage currently has a sector perform rating on the stock.

Several other equities research analysts have also commented on the stock. Evercore ISI set a $32.00 price target on shares of Moderna in a report on Friday, August 1st. Barclays cut their price objective on Moderna from $31.00 to $25.00 and set an “equal weight” rating for the company in a research note on Friday, November 7th. Piper Sandler reissued an “overweight” rating and issued a $63.00 price target (down from $69.00) on shares of Moderna in a research note on Friday. Bank of America cut their target price on Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research note on Monday, November 10th. Finally, Wolfe Research reaffirmed an “underperform” rating and set a $17.00 price target on shares of Moderna in a research report on Thursday. Two equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $29.46.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $23.72 on Friday. Moderna has a 1 year low of $22.28 and a 1 year high of $48.92. The firm has a market capitalization of $9.27 billion, a P/E ratio of -2.94 and a beta of 2.02. The business’s 50-day moving average is $25.87 and its 200 day moving average is $26.98.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 6th. The company reported ($0.51) EPS for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. Moderna’s revenue for the quarter was down 45.4% on a year-over-year basis. During the same period last year, the business earned $0.03 EPS. Moderna has set its FY 2025 guidance at EPS. On average, analysts expect that Moderna will post -9.61 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. CIBC Bancorp USA Inc. purchased a new position in shares of Moderna in the 3rd quarter valued at about $913,000. Centaurus Financial Inc. raised its stake in shares of Moderna by 162.0% during the third quarter. Centaurus Financial Inc. now owns 16,184 shares of the company’s stock worth $418,000 after purchasing an additional 10,007 shares during the last quarter. Coldstream Capital Management Inc. lifted its stake in shares of Moderna by 31.3% in the 3rd quarter. Coldstream Capital Management Inc. now owns 9,525 shares of the company’s stock worth $246,000 after acquiring an additional 2,272 shares during the period. Danske Bank A S purchased a new stake in Moderna in the 3rd quarter valued at approximately $157,000. Finally, Jacobs Levy Equity Management Inc. grew its holdings in Moderna by 7.7% during the third quarter. Jacobs Levy Equity Management Inc. now owns 1,449,931 shares of the company’s stock worth $37,452,000 after acquiring an additional 103,981 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.